Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_assertion type Assertion NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_head.
- NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_assertion description "[Furthermore, Hsp90 inhibitors 17-AAG [17-(allylamino)-17-demethoxygeldanamycin] and STA-9090 significantly reduced the growth of myeloid leukemia xenografts in vivo and effectively down-regulated the expression of WT1 and its downstream target proteins, c-Myc and Bcl-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_provenance.
- NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_assertion evidence source_evidence_literature NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_provenance.
- NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_assertion SIO_000772 20651072 NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_provenance.
- NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_assertion wasDerivedFrom befree-20140225 NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_provenance.
- NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_assertion wasGeneratedBy ECO_0000203 NP239167.RA0wALS0jK0iJY9b69YltIrx2bbw53TlF2vx1IGvgfiHA130_provenance.